{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:18:28Z","timestamp":1793038708396,"version":"4.5.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To report the results of the survey for the role of anti-VEGF in the management of retinopathy of prematurity (ROP) among the members of Indian ROP (iROP) society.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A questionnaire was designed in English using Google forms and its link was circulated to the members of the iROP society on their mobile numbers. The survey included questions pertaining to demographics, anti-VEGF agents, injection technique, post-injection follow-up, and documentation pertaining to their ROP practice. Anonymous responses were obtained and analyzed for individual questions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>226 members of the society were contacted and 157 responded (69.4%) to the survey. 137 (87.2%) respondents used anti-VEGF in the management of ROP. Aggressive posterior ROP (APROP) was the most common indication (78, 52.7%). The procedure was carried out in the main operation room (102, 70.3%) simultaneously for both the eyes (97; 68%) under topical anesthesia (134; 86.4%) by most of the respondents. One-hundred thirteen (77.9%) respondents used half of the adult dose, irrespective of the agent used; however, more than half of them preferred bevacizumab (85, 54%). 53 (36.3%) respondents followed up infants as per disease severity rather than a fixed schedule while only 33 (23%) performed photo documentation. 151 (96.2%) respondents felt the need for guidelines regarding the usage of anti-VEGF in ROP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>There is an increase in the trend towards the use of anti-VEGF in the management of severe ROP, particularly APROP. However, there are considerable variations among the ROP practitioners regarding the agent, dosage, follow-up schedule, and documentation, suggesting the need for uniform guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_200_21","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T10:22:48Z","timestamp":1627899768000},"page":"2158-2163","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: A survey among the members of Indian Retinopathy of Prematurity Society"],"prefix":"10.4103","volume":"69","author":[{"given":"Anil","family":"Gangwe","sequence":"first","affiliation":[{"name":"Vitreoretina Services, MGM Eye Institute, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepanshu","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Vitreoretina Services, MGM Eye Institute, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Vinekar","sequence":"additional","affiliation":[{"name":"Department of Pediatric Retina, Narayana Nethralaya Eye Institute, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj V","family":"Azad","sequence":"additional","affiliation":[{"name":"Raj Retina Eye Care Hospital, Patna, Bihar, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil M","family":"Parchand","sequence":"additional","affiliation":[{"name":"Vitreoretina Services, MGM Eye Institute, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepshikha","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Director, MGM Eye Institute, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"B1-20240828","first-page":"S89","article-title":"Update on blindness due to retinopathy of prematurity globally and in India","volume":"53","author":"Blencowe","year":"2016","journal-title":"Indian Pediatr"},{"key":"B2-20240828","doi-asserted-by":"crossref","first-page":"254","DOI":"10.4103\/0301-4738.128639","article-title":"Aggressive posterior retinopathy of prematurity in infants \u22651500 g birth weight","volume":"62","author":"Sanghi","year":"2014","journal-title":"Indian J Ophthalmol"},{"key":"B3-20240828","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4103\/0301-4738.33817","article-title":"Retinopathy of prematurity in Asian Indian babies weighing greater than 1250 grams at birth:Ten-year data from a tertiary care center in a developing country","volume":"55","author":"Vinekar","year":"2007","journal-title":"Indian J Ophthalmol"},{"key":"B4-20240828","doi-asserted-by":"crossref","first-page":"F371","DOI":"10.1136\/fetalneonatal-2011-301121","article-title":"Aggressive posterior retinopathy of prematurity in large preterm babies in South India","volume":"97","author":"Shah","year":"2012","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"B5-20240828","doi-asserted-by":"crossref","first-page":"27","DOI":"10.21037\/aes.2017.04.02","article-title":"The Indian retinopathy of prematurity society:A baby step towards tackling the retinopathy of prematurity epidemic in India","volume":"2","author":"Vinekar","year":"2017","journal-title":"Ann Eye Sci"},{"key":"B6-20240828","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity:Results of early treatment for ROP randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"B7-20240828","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1001\/archopht.1990.01070120056029","article-title":"One-year outcome--structure and function. Cryotherapy for Retinopathy of Prematurity Cooperative Group","volume":"108","year":"1990","journal-title":"Arch Ophthalmol"},{"key":"B8-20240828","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jcjo.2018.03.005","article-title":"Posterior zone I retinopathy of prematurity:Spectrum of disease and outcome after laser treatment","volume":"54","author":"Katoch","year":"2019","journal-title":"Can J Ophthalmol"},{"key":"B9-20240828","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ajo.2006.02.018","article-title":"Retinopathy of prematurity:Two distinct mechanisms that underlie zone 1 and zone 2 disease","volume":"142","author":"Flynn","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"B10-20240828","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal Bevacizumab for stage 3+retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"B11-20240828","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birth weight infants with retinopathy of prematurity (RAINBOW):An open-label randomized controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"B12-20240828","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents:A review of the literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye (Lond)"},{"key":"B13-20240828","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","article-title":"A dosing study of bevacizumab for retinopathy of prematurity:Late recurrences and additional treatments","volume":"125","author":"Wallace","year":"2018","journal-title":"Ophthalmology"},{"key":"B14-20240828","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity:A report by the American Academy of Ophthalmology","volume":"124","author":"VanderVeen","year":"2017","journal-title":"Ophthalmology"},{"key":"B15-20240828","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.oret.2017.11.012","article-title":"Analysis of the recurrence of plus disease after intravitreal ranibizumab as a primary monotherapy for severe retinopathy of prematurity","volume":"2","author":"Ar\u00e1mbulo","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"B16-20240828","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.oret.2019.03.013","article-title":"Current practice p and safety protocols for intravitreal injection of anti-vascular endothelial growth factor agents","volume":"3","author":"Uhr","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"B17-20240828","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2147\/OPTH.S161504","article-title":"Retinopathy of prematurity:Preferred practice patterns among pediatric ophthalmologists","volume":"12","author":"Fouzdar Jain","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"B18-20240828","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/bjophthalmol-2011-300321","article-title":"A Hybrid form of retinopathy of prematurity","volume":"96","author":"Sanghi","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"B19-20240828","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/1120672118770557","article-title":"Systematic review and meta-analysis of the negative outcomes of retinopathy of prematurity treated with laser photocoagulation","volume":"29","author":"Liang","year":"2019","journal-title":"Eur J Ophthalmol"},{"key":"B20-20240828","first-page":"CD009734","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for the treatment of retinopathy of prematurity","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B21-20240828","first-page":"CD009734","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for the treatment of retinopathy of prematurity","volume":"2","author":"Sankar","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B22-20240828","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ajo.2012.07.012","article-title":"Aggressive posterior retinopathy of prematurity:Risk factors for retinal detachment despite confluent laser photocoagulation","volume":"155","author":"Sanghi","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"B23-20240828","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.siny.2015.05.002","article-title":"Role of tele-medicine in retinopathy of prematurity screening in rural outreach centers in India-A report of 20,214 imaging sessions in the KIDROP program","volume":"20","author":"Vinekar","year":"2015","journal-title":"Semin Fetal Neonatal Med"},{"key":"B24-20240828","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3928\/23258160-20160419-16","article-title":"Current practice patterns for treatment of retinopathy of prematurity","volume":"47","author":"Tawse","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"B25-20240828","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4103\/0970-258X.239079","article-title":"Intraocular use of Bevacizumab in India:An issue resolved?","volume":"30","author":"Kumar","year":"2017","journal-title":"Natl Med J India"},{"key":"B26-20240828","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4103\/ijo.IJO_1232_19","article-title":"Imaging the ora serrata with the 3Nethra Neo camera-Importance in screening and treatment in retinopathy of prematurity","volume":"68","author":"Vinekar","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"B27-20240828","doi-asserted-by":"crossref","first-page":"e20161978","DOI":"10.1542\/peds.2016-1978","article-title":"Trends in the screening and treatment of retinopathy of prematurity","volume":"139","author":"Vartanian","year":"2017","journal-title":"Pediatrics"},{"key":"B28-20240828","first-page":"3169","article-title":"Methods and techniques for intravitreal antiangiogenic therapy (IAT) in retinopathy of prematurity (ROP):A 196 cases experience","volume":"52","author":"Mercado","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B30-20240828","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.oret.2017.09.021","article-title":"Supplemental laser for eyes treated with bevacizumab monotherapy in severe retinopathy of prematurity","volume":"2","author":"Tandon","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"B31-20240828","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/bjophthalmol-2017-310408","article-title":"Ultra-low-dose intravitreal Bevacizumab for the treatment of retinopathy of prematurity:A case series","volume":"102","author":"Hillier","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"B32-20240828","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity:Comparison between Ranibizumab and Bevacizumab","volume":"35","author":"Chen","year":"2015","journal-title":"Retina"},{"key":"B33-20240828","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","article-title":"Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity (CARE-ROP) study group:A randomized clinical trial","volume":"172","author":"Stahl","year":"2018","journal-title":"JAMA Paediatr"},{"key":"B34-20240828","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/IAE.0000000000001125","article-title":"Outcomes after laser versus combined laser and bevacizumab treatment for type 1 retinopathy of prematurity in zone I","volume":"37","author":"Yoon","year":"2017","journal-title":"Retina"},{"key":"B36-20240828","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/eye.2015.240","article-title":"Serial evaluation of retinal vascular changes in infants treated with intravitreal Bevacizumab for aggressive posterior retinopathy of prematurity in zone I","volume":"30","author":"Padhi","year":"2016","journal-title":"Eye (Lond)"},{"key":"B37-20240828","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jcjo.2017.02.012","article-title":"Low-dose Ranibizumab as primary treatment of posterior type I retinopathy of prematurity","volume":"52","author":"Ells","year":"2017","journal-title":"Can J Ophthalmol"},{"key":"B38-20240828","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1167\/iovs.16-20680","article-title":"Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy:Timing and risk factors","volume":"58","author":"Lyu","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B39-20240828","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4103\/tjo.tjo_69_18","article-title":"Bevacizumab or laser for aggressive posterior retinopathy of prematurity","volume":"8","author":"Blair","year":"2018","journal-title":"Taiwan J Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_200_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:29:54Z","timestamp":1786735794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_200_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_200_21","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"2021-01-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}